Studies show that patients with the same type of cancer can have very different outcomes, even with the same treatment. Now physicians and researchers are developing personalized medicine treatment plans for each patient based on the molecular markers of their tumor. Sponsored by The University of Texas M. D. Anderson Cancer Center, this Patient Power program features Dr. Gordon Mills, chairman of the Department of Systems Biology and director of the Kleberg Center for Molecular Markers.
The program begins with Sonia, a breast cancer patient treated at M. D. Anderson. She talks about working with her team of oncologists to find the most appropriate therapy based on her individual cancer. You’ll hear about Sonia’s specific treatment, including surgery and chemotherapy, and how she’s doing today.
Dr. Mills discusses Sonia’s treatment and what HER (Human Epidermal Growth Factor Receptor) means as related to breast cancer. He helps us to understand how doctors develop a personalized treatment plan for cancer treatment, using genetic information and a series of that person’s tumor molecular markers for tumor classification. Dr. Mills and his team are working hard to identify those at high risk for developing cancer, how to diagnose at earlier stages, and how to get the right drug to to the right patient based on their tumor and genetic makeup to increase efficacy. Learn how cancer treatment is changing, not only for breast and ovarian cancer, but for lung and brain cancer, among many others. If you’re searching for information on new treatment choices, this program will be a good resource.
Gordon Mills, M.D., Ph.D.
Chairman, Department of Molecular Therapeutics, MD Anderson Cancer CenterDr. Mills is Chairman of the Department of Molecular Therapeutics and Professor of Medicine at the M.D. Anderson Cancer Center. He received both his medical degree and his doctorate in Biochemistry from the University of Alberta, Canada. more >